First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma

(MedPage Today) — The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced.
The subcutaneous anti-interleukin…